Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20(+) tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR)...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892878/
https://www.ncbi.nlm.nih.gov/pubmed/33602901
http://dx.doi.org/10.1038/s41408-021-00430-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892878/
https://www.ncbi.nlm.nih.gov/pubmed/33602901
http://dx.doi.org/10.1038/s41408-021-00430-6

Ejemplares similares